(Remove extraneous words at the end of story)
Nov 19 (Reuters) – Sanofi is weighing an acquisition of US drugmaker Insmed, Bloomberg News reported on Thursday, citing people familiar with the matter.
Shares of Insmed, which has a market valuation of $26.28 billion according to LSEG data, were up 16%. The companies did not immediately respond to Reuters’ requests for comment.
French drugmaker Sanofi is speaking with advisers as it studies a potential deal for Insmed, Bloomberg reported, citing the people, who asked not to be identified discussing confidential information.
Deliberations are ongoing and any deal could still be weeks away, the report added.
(Reporting by Sneha S K; Editing by Maju Samuel)

